Open Actively Recruiting

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]


Brief Summary

Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of blindness in patients over 65 years of age. The abnormal angiogenic process in nAMD is stimulated and modulated by vascular endothelial growth factor (VEGF). Treatment of nAMD requires frequent intravitreal (IVT) injections of VEGF inhibitors (anti-VEGF) administered every 4-12 weeks. ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product being developed for the treatment of nAMD and offers the potential for sustained intraocular expression of aflibercept following a single IVT injection. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.

Primary Purpose
Study Type
Phase 2


Healthy Volunteers
Minimum Age
50 Years
Maximum Age

Inclusion Criteria:

  • Male or female participants, ≥ 50 years of age
  • Willing and able to provide written, signed informed consent for this study
  • Demonstrated a meaningful response to anti-VEGF therapy.
  • Participants must be under active anti-VEGF treatment for wet AMD and received a minimum of 3 injections within 6 months prior to screening for the treatment of choroidal neovascularization secondary to nAMD
  • BCVA ETDRS Snellen equivalent between ≤20/32 and ≥20/320

Exclusion Criteria:

  • Any condition that could affect the interpretation of results or render the participant at high risk of treatment complications in the opinion of the Investigator
  • Ocular or periocular infection or intraocular inflammation in either eye within 1 month prior to or at the Randomization Visit (Day -7)
  • Uncontrolled diabetes or HbA1c ≥ 7.0 %
  • History or evidence of significant uncontrolled concomitant disease within 6 months of the Screening visit
  • Any history of ongoing bleeding disorders or INR >3.0
  • History or evidence of macular or retinal disease other than nAMD
  • Active or history of retinal detachment or retinal pigment epithelium rip/tear
  • Uncontrolled ocular hypertension or glaucoma
  • Prior treatment with photodynamic therapy or retinal laser for the treatment of nAMD
  • Any history of vitrectomy or any other vitreoretinal surgery within 3 months prior to the Randomization Visit (Day -7)
  • Prior treatment with gene therapy at any time or any non-gene therapy investigational treatment or medical device in the study eye within 3 months of the Screening Visit or 5 half-lives of the investigational medicinal product

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
Karina Lozano
  • UCLA Westwood
For Providers
For detailed technical eligibility, visit